Table 3—

Baseline characteristics of patients by exacerbation group

NoneUnreported onlyReported onlyMixed#
1>11>1
Subjects n1673045704692
Age yrs64.8±11.463.0±10.863.5±10.868.6±8.9*65.7±9.964.7±10.3
Male sex110 (67.0)21 (70.0)37 (82.2)*38 (54.3)33 (71.7)70 (73.6)
Cumulative smoking pack-yrs29.1±34.925.6±20.420.1±23.821.7±24.1*18.0±24.9*29.1±27.2
MRC dyspnoea score ≥429 (17.6)7 (23.3)7 (15.5)19 (27.1)11 (23.9)30 (31.5)*
6MWD m398.7±139.3369.7±85.6437.2±130.7348.6±119.2*356.6±121.5414.2±138.1
Spirometry (post-BD)
 FEV1 L1.19±0.471.32±0.551.28±0.421.10±0.451.06±0.531.19±0.46
 FEV1 % pred48.3±15.153.7±18.448.1±14.649.6±16.144.3±15.547.5±16.0
 FVC L2.34±0.792.62±0.782.65±0.69*2.13±0.792.20±0.832.47±0.77
 FVC % pred74.9±19.684.0±19.8*78.0±17.575.0±20.974.9±16.778.2±18.6
 FEV1/FVC0.51±0.100.48±0.110.50±0.100.52±0.090.47±0.100.48±0.12*
Hospital admission for last exacerbation66 (40.2)9 (30.0)23 (51.1)33 (47.1)28 (60.9)*53 (55.7)*
Significant comorbid conditions ≥123 (14.0)6 (20.0)6 (13.3)12 (17.1)7 (15.2)19 (20.0)
Treatment profile
 LABD62 (37.8)13 (43.3)17 (37.8)42 (60.0)**31 (67.4)**46 (48.4)
 ICS50 (30.5)9 (30.0)8 (17.8)26 (37.1)17 (37.0)32 (33.7)
 Mucolytics74 (45.1)10 (33.3)20 (44.4)43 (61.4)*32 (70.0)**45 (47.3)
 No medication+47 (28.1)10 (33.3)15 (33.3)15 (21.4)4 (8.7)25 (27.2)
  • Data are presented as mean±sd or n (%), unless otherwise indicated (n = 450). MRC: UK Medical Research Council; 6MWD: 6-min walking distance; BD: bronchodilator; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; LABD: long-acting bronchodilator; ICS: inhaled corticosteroid. #: unreported (≥1) and reported (≥1); : analyses were conducted amongst patients who had complete baseline data for 6MWD; +: no use of LABDs, ICSs or mucolytics. *: p<0.05; **: p<0.01 versus no exacerbations (reference) using unpaired two-tailed t-test for comparison of continuous variables (two means) and Chi-squared test for comparison of categorical variables (two proportions).